Latest news with #NovoCare
Business Insider
02-07-2025
- Business
- Business Insider
Novo Nordisk, WeightWatchers expand collaboration
WW International (WGHTH) 'announced an expanded collaboration with Novo Nordisk (NVO), which includes increased access to authentic, FDA-approved Wegovy injection through WeightWatchers (WGHTQ) Clinic. As the only holistic platform focused on long-term weight health featuring the No. 1 doctor-recommended weight loss program included in the recently announced collaboration with Novo Nordisk, WeightWatchers continues to reinforce its role as the trusted leader in sustainable, science-backed weight care, and one of the few in the industry to publicly commit to prescribing only FDA-approved medications. As part of the collaboration, WeightWatchers Clinic members will benefit from a simplified prescription process via NovoCare Pharmacy. CenterWell Pharmacy, a seven-time MMIT Specialty Pharmacy Patient Choice Award winner for best-in-class customer satisfaction and commitment to patient care, serves as the dispensing pharmacy for the NovoCare program and will facilitate direct fulfillment and home delivery of Wegovy prescriptions for WeightWatchers Clinic members. In addition, WeightWatchers will enhance the member experience by providing integrated account access, bundled pricing opportunities, inventory visibility, and shipment tracking. Additionally, Novo Nordisk is offering a limited-time savings offer available to WeightWatchers Clinic members. Starting July 1, 2025, eligible cash-pay members can access Wegovy at a reduced price of $299 until July 31, 2025-a significant savings aimed at expanding access to clinically validated, FDA-regulated treatment options.'
Yahoo
18-06-2025
- Business
- Yahoo
Novo Nordisk seeks digital health partners to boost GLP-1RA weight loss outcomes
Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients lose weight more effectively and stay on track with its flagship medication, Wegovy (semaglutide). The Novo Nordisk Partner Platform (NNPP) was announced at HLTH Europe, taking place in Amsterdam from 16 to 19 June, by Anne Cathrine Fleischer, vice president of Global Obesity Consumer Engagement and New Business Models at Novo Nordisk. Fleischer said that the programme will provide more services for patients receiving its glucagon-like peptide 1 receptor agonist (GLP-1RA) semaglutide, which is marketed as Wegovy for weight loss and Ozempic in type 2 diabetes, including fitness and dietary advice. Fleischer explained: 'The idea is that we create this ecosystem or marketplace of selected solutions that people can pick and choose from, so when a patient has started treatment, we know they have received help. We know when we look at our own digital tools that when intervention is combined with those efficient weight loss medications, patients are receiving better weight loss, so we hope we can significantly improve outcomes by combining education with digital tools.' Fleischer said that while this will be available to patients through the Novo Nordisk website or Novo Care, there are also considerations to work with an app developer to ensure all the services are available in one place. 'By partnering with these players, we can provide a much better patient journey and care pathway,' Fleischer added. Novo Nordisk is hoping to partner with a company which uses artificial intelligence (AI) to scan a person's plate of food and provide them with information as to whether it is providing the necessary nutrition, notably protein, due to GLP-1RAs' association with loss of muscle mass. Novo Nordisk is also in conversation with a company offering a body composition scanner mobile app. The pharma giant is also seeking telehealth providers and pharmacies to provide medical advice to patients receiving the therapy. Novo Nordisk aims to cement itself as the leading weight loss company globally after Eli Lilly announced its therapy Zepbound (tirzepatide) resulted in more weight loss than Wegovy in a Phase III study. Earlier in June, Novo Nordisk accelerated its subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity and overweight. It recently initiated two more Phase III trials of its candidate CagriSema, as well as inking an $812m partnership with Deep Apple Therapeutics to access novel compounds, not GLP-1RAs, for obesity and other diseases. The company also announced a partnership with tech heavyweight NVIDIA to advance drug discovery using cutting-edge AI technologies. "Novo Nordisk seeks digital health partners to boost GLP-1RA weight loss outcomes" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Daily Mail
29-04-2025
- Business
- Daily Mail
America set for Ozempic EXPLOSION as drug is made available on telehealth giant for first time
The weight loss drug market is set to explode further with the announcement that Wegovy is set to be available via telehealth platforms at more affordable rates. Danish drug giant Novo Nordisk has revealed that working with online firms Hims & Hers, Ro and LifeMD to sell Wegovy, as it looks to stem sales of copies of its popular weight-loss drug and expand access to cash-paying patients. Hims & Hers said it will begin offering all doses of Wegovy this week, starting at $599 per month to eligible cash-paying patients with a prescription. Ro and LifeMD said they would offer access to all doses of the drug - which is a stronger version of Ozempic - for $499 per month. These offers will be available for uninsured patients or eligible patients with commercial insurance who do not have coverage for obesity medicines. Currently Wegovy has a list price of around $1,350 for a 28-day supply. This means that the medication could cost more than $16,000 per year without insurance or manufacturer discounts. GLP-1 drugs do require a prescription but all people have to do via telehealth platforms is make an online appointment with a doctor, see them briefly over a video chat and get an order signed off. Rival drugmaker Eli Lilly has made similar moves to make its obesity drug Zepbound more accessible to cash-paying patients, including working with Ro to offer the medicine through its platform. Shares of Hims & Hers jumped more than 25 percent in afternoon trading on announcement of the Wegovy launch, while LifeMD shares rose more than 36 percent. A US judge last week rejected a bid by compounding pharmacies to keep selling copies of Wegovy while a legal challenge over drug shortages plays out. Compounding pharmacies had been allowed to produce hundreds of thousands of doses of their versions of Novo's obesity and diabetes drugs while the FDA said the medicines were in short supply. Larger so-called outsourcing facilities, which make compounded drugs in bulk to sell to telehealth companies and others, have been given until May 22 to cease making the drug, while smaller compounding pharmacies must stop immediately. Hims & Hers and Ro started selling compounded versions of semaglutide, the active ingredient in Wegovy and Novo's diabetes drug Ozempic, last year. Hims CEO Andrew Dudum said the company will continue to offer personalized compounded versions of semaglutide on its platform. In an effort to make Wegovy more accessible to cash-paying patients earlier this year, Novo Nordisk launched its NovoCare pharmacy program to supply the drug at a reduced cost of $499. Later in March, it extended the offer to all eligible cash-paying customers at their local pharmacy. Patients can now access NovoCare directly through the three telehealth platforms. 'This should also be a very clear message that we have full supply of Wegovy... we want everyone to know that all doses are available,' Dave Moore, executive vice president of US operations for the Danish drugmaker said.
Bloomberg
29-04-2025
- Business
- Bloomberg
Novo Nordisk Teams With Telehealth Firms Hims, Ro to Sell Wegovy at Lower Price
Hims & Hers Health Inc. soared in pre-market trading after Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a reduced price on several telehealth platforms. Through NovoCare, Novo's new direct-to-consumer pharmacy platform, Hims, LifeMD Inc., and Ro will each sell a month's supply of Wegovy starting at $499. That's a 63% discount from the drug's US list price, before additional subscription fees.
Forbes
29-04-2025
- Business
- Forbes
Humana's CenterWell Expands Specialty Pharmacy As GLP-1 Drugs Take Off
Humana's CenterWell healthcare services business Tuesday said it would expand beyond its traditional ... More home-delivery pharmacy services business and will begin filling and shipping orders for the popular GLP-1 weight loss drug Wegovy that are prescribed through three telehealth companies: Hims & Hers Health, Inc., LifeMD and Ro. In this photo are images of Novo Nordisk's Wegovy, an injectable prescription weight loss medicine that has helped people with obesity. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) Humana is the latest health insurer to expand into the fast-growing and lucrative business of direct-to-patient specialty pharmacy as demand grows for popular GLP-1 weight loss drugs. Humana's CenterWell healthcare services business Tuesday said it would expand beyond its traditional home-delivery pharmacy services business and will begin filling and shipping orders for the popular GLP-1 weight loss drug Wegovy that are prescribed through three telehealth companies: Hims & Hers Health, Inc., LifeMD and Ro. The partnership was disclosed by Humana and Novo Nordisk that CenterWell Pharmacy will be its fulfillment partner for NovoCare, a pharmacy the drug maker launched a month ago to provide 'direct-to-patient, convenient home shipments of all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients,' Novo Nordisk said last month. CenterWell pharmacy's partnership with Novo Nordisk is directed at cash-paying consumers, or what the industry calls 'self-pay' patients, who don't have health insurance coverage for anti-obesity drugs, which are dropping in price but even with discounts cost several hundred dollars an injection. 'Under the arrangement, CenterWell is helping consumers benefit from reduced cost and convenient access to safe and effective brand-name medications,' CenterWell pharmacy senior vice president Guillermo Sollberger said in a statement released during the annual at Asembia ASX25, which draws more than 8,000 companies tied to the specialty pharmacy industry this week to Las Vegas. The partnership also comes in the wake of the Trump White House's decision earlier this month to scrap a Biden administration proposal to have Medicare health plans for seniors and Medicaid insurance for low-income Americans cover weight loss drugs such as Novo Nordisk's Wegovy. CenterWell and Novo Nordisk see 'direct-to-patient' partnerships as a way to expand access to those without health insurance coverage for certain prescriptions. Novocare follows a similar effort launched last year called LillyDirect, a direct-to-patient effort from Eli Lilly, maker of the GLP-1 drug Zepbound. 'NovoCare Pharmacy is a direct-to-patient delivery option that offers cash-paying patients the GLP-1 medication, Wegovy, at a reduced cost of $499 per month,' Sollberger said. 'Under the arrangement, CenterWell is helping consumers benefit from reduced cost and convenient access to safe and effective brand-name medications.' It's the latest health insurer to expand deeper into specialty pharmacy. Already, UnitedHealth Group's OptumRx and CVS Health, which owns the health insurer Aetna, have expanded more into specialty pharmacy. Optum, for example, has 15 Optum Specialty Pharmacies and two 'Optum Frontier Therapies' that the company says help patients with rare and complex conditions, helping them access more than 200 specialty drugs. And Cigna, which owns Evernorth health services, has expanded its Accredo Specialty Pharmacy since it was part of the company's 2018 Express Scripts purchase and today serves 900,000 patients and ships 7 million prescriptions annually. Meanwhile, And a year ago, Elevance Health, which operates Anthem Blue Cross and Blue Shield plans, a year ago bought the grocery chain Kroger's specialty pharmacy and the year before bought BioPlus. Eventually, drug makers and pharmacies see direct-to-patient models emerging for other new medicines, particularly as technology advances like telehealth that allows Americans to more easily obtain prescription drugs. 'Direct-to-patient distribution models like this are likely to evolve beyond GLP-1s to include other medication categories like migraine therapies and women's/men's health,' CenterWell's Sollberger said. 'CenterWell Pharmacy is well positioned to scale such programs, with the agility to meet the needs of this growing market.'
